Farnaby, William

Team Leader, Biological Chemistry and Drug Discovery

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where William Farnaby is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

12 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or

180 Citations
5 h-Index
6 Article
1 Editorial
1 Review article

Transforming targeted cancer therapy with PROTACs: A forward-looking perspective
Farnaby, W., Koegl, M., McConnell, D. B. & Ciulli, A., Apr 2021, In: Current Opinion in Pharmacology. 57, p. 175-183 9 p.
Research output: Contribution to journal › Review article › peer-review
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., Gmaschitz, T., Wachter, J., Dank, C., Galant, M., Sharps, B., Rumpel, K., Traxler, E., Gerstberger, T., Schnitzer, R., Petermann, O. & 17 others, Greb, P., Weinstabl, H., Bader, G., Zoephel, A., Weiss-Puxbaum, A., Ehrenhöfer-Wölfer, K., Wöhrle, S., Boehmelt, G., Rinnenthal, J., Arnhof, H., Wiechens, N., Wu, M-Y., Owen-Hughes, T., Ettmayer, P., Pearson, M., McConnell, D. B. & Ciulli, A., Jul 2019, In: Nature Chemical Biology. 15, 7, p. 672-680 9 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
86 Citations (Scopus)

100 Downloads (Pure)
Protein degradation for drug discovery
Ciulli, A. & Farnaby, W., Apr 2019, In: Drug Discovery Today: Technologies. 31, p. 1-3 3 p.
Research output: Contribution to journal › Editorial › peer-review

5 Citations (Scopus)
Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-oezguer, J., Riedmueller, C., Gmaschitz, T., Wachter, J., Dank, C., Galant, M., Sharps, B., Rumpel, K., Traxler, E., Gerstberger, T., Schnitzer, R., Petermann, O. & 17 others, Greb, P., Weinstabl, H., Bader, G., Zoephel, A., Weiss-Puxbaum, A., Ehrenhöfer-Wölfer, K., Wöhrle, S., Boehmelt, G., Rinnenthal, J., Arnhof, H., Wiechens, N., Wu, M-Y., Owen-Hughes, T., Ettmayer, P., Pearson, M., Mcconnell, D. B. & Ciulli, A., 2 Jul 2019, In: Nature Chemical Biology. 15, 8, p. 846 1 p.
Research output: Contribution to journal › Article › peer-review
3 Citations (Scopus)
SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate
Roy, M., Winkler, S., Hughes, S. J., Whitworth, C., Galant, M., Farnaby, W., Rumpel, K. & Ciulli, A., 15 Mar 2019, In: ACS Chemical Biology. 14, 3, p. 361-368 8 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
53 Citations (Scopus)

393 Downloads (Pure)

Transforming targeted cancer therapy with PROTACs: A forward-looking perspective

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

Protein degradation for drug discovery

Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate